Precigen (PGEN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Precigen

NasdaqGS•Healthcare•Biotechnology

$7.87+0.43(0.06%)After hours

Market Cap

$2.50B

P/S

28.5x

P/B

57.3x

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Growth (16/25); weakest: Profitability (3/25).

Profitability3/25

Growth16/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality4/25

Strengths

Growing revenueConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 11.8x5y range 9.3x – 16.2x

Currently near its 4-quarter median.

P/S · 28.5x5y range 3.4x – 6736.6x

Currently near its 13-quarter median.

P/B · 57.3x5y range 1.3x – 63.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.50B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $87.67M
Q. Revenue: $54.98M
TTM EBITDA: $-35.36M
TTM Op. Income: $-39.50M
Q. Op. Income: $22.64M
TTM Net Income: $-157.71M
Q. Net Income: $20.07M
EPS: $0.06
Shares Out.: $356.89M

$87.67M in TTM revenue grew 116793.3% YoY, reaching $54.98M last quarter. TTM EBITDA of $-35.36M and TTM operating income of $-39.50M show growth is flowing through to the bottom line. However, net income is negative at $157.71M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 43.2%
Op. Margin: 41.2%
Net Margin: 36.5%

Op. margin of 41.2% is up 77514.4% YoY — cost efficiency is improving. Net margin at 36.5% Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 28.5x
P/B Ratio: 57.3x

P/S of 28.5x and P/B of 57.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $170.30M
Cash: $16.33M
Long-Term Debt: $93.88M
Book Value: $43.58M
D/E Ratio: 2.2
Debt/EBITDA: 4.0

With $170.30M in assets and $93.88M in long-term debt, D/E is 2.2and book value is $43.58M — elevated leverage, meaning significant financial risk in a downturn. Over the past year, debt/equity is up 0% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-17.81M
TTM Free Cash Flow: $-115.22M
FCF Margin: -131.4%
FCF / Net Income: 0.7

TTM FCF of $-115.22M on $-17.81M in operating cash flow. The FCF / Net Income ratio of 0.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 65% — an improving trend.